<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/" version="2.0">
  <channel>
    <title>topic Calculate Sample size for non-inferiority clinical trial (with given Hazard ratio margin) in Statistical Procedures</title>
    <link>https://communities.sas.com/t5/Statistical-Procedures/Calculate-Sample-size-for-non-inferiority-clinical-trial-with/m-p/754938#M36752</link>
    <description>&lt;P&gt;Hi,&lt;/P&gt;
&lt;P&gt;Could anyone show me how to calculate sample size for a non-inferiority clinical trial with given information as following?&lt;/P&gt;
&lt;P&gt;"&lt;SPAN&gt;The primary hypothesis aims to show non-inferiority on 3P-MACE for empagliflozin versus placebo based on a non-inferiority margin of &amp;lt; 1.3 (upper limit of the adjusted 95% confidence interval (CI)) for the hazard ratio. The upper limit of the adjusted 95% CI for the HR of &amp;lt;1.3 was based on FDA guidance for CV trials evaluating new anti-hyperglycemic therapies for T2DM [&lt;/SPAN&gt;&lt;A class=" bibr popnode" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072621/#B9" target="_blank"&gt;9&lt;/A&gt;&lt;SPAN&gt;]. Patients who receive either 10&amp;nbsp;mg or 25&amp;nbsp;mg of&amp;nbsp;&lt;/SPAN&gt;&lt;SPAN&gt;empagliflozin will be pooled into a common treatment group for the purposes of the primary analysis. A 4-step hierarchical testing strategy will be followed: 1) non-inferiority test of the primary outcome (3P-MACE), 2) non-inferiority test of the key secondary outcome (4P-MACE), 3) superiority test of the primary outcome (3P-MACE) and 4) superiority test of the key secondary outcome (4P-MACE). &lt;STRONG&gt;A minimum of 691 confirmed primary outcome events are required&lt;/STRONG&gt; to provide 90% power with a one-sided α level of 0.025, assuming equal risk between the placebo and empagliflozin groups. With a minimum of 691 events, the trial will also have at least 80% power to detect a hazard ratio of 0.785 (corresponding to a 21.5% risk reduction in CV outcome events) for the primary outcome."&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;SPAN&gt;So actually how to get the number of 691 as stated in the article?&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;SPAN&gt;Thanks a lot for your kinda help.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN&gt;Trang&amp;nbsp;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;</description>
    <pubDate>Mon, 19 Jul 2021 09:15:59 GMT</pubDate>
    <dc:creator>Minhtrang</dc:creator>
    <dc:date>2021-07-19T09:15:59Z</dc:date>
    <item>
      <title>Calculate Sample size for non-inferiority clinical trial (with given Hazard ratio margin)</title>
      <link>https://communities.sas.com/t5/Statistical-Procedures/Calculate-Sample-size-for-non-inferiority-clinical-trial-with/m-p/754938#M36752</link>
      <description>&lt;P&gt;Hi,&lt;/P&gt;
&lt;P&gt;Could anyone show me how to calculate sample size for a non-inferiority clinical trial with given information as following?&lt;/P&gt;
&lt;P&gt;"&lt;SPAN&gt;The primary hypothesis aims to show non-inferiority on 3P-MACE for empagliflozin versus placebo based on a non-inferiority margin of &amp;lt; 1.3 (upper limit of the adjusted 95% confidence interval (CI)) for the hazard ratio. The upper limit of the adjusted 95% CI for the HR of &amp;lt;1.3 was based on FDA guidance for CV trials evaluating new anti-hyperglycemic therapies for T2DM [&lt;/SPAN&gt;&lt;A class=" bibr popnode" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072621/#B9" target="_blank"&gt;9&lt;/A&gt;&lt;SPAN&gt;]. Patients who receive either 10&amp;nbsp;mg or 25&amp;nbsp;mg of&amp;nbsp;&lt;/SPAN&gt;&lt;SPAN&gt;empagliflozin will be pooled into a common treatment group for the purposes of the primary analysis. A 4-step hierarchical testing strategy will be followed: 1) non-inferiority test of the primary outcome (3P-MACE), 2) non-inferiority test of the key secondary outcome (4P-MACE), 3) superiority test of the primary outcome (3P-MACE) and 4) superiority test of the key secondary outcome (4P-MACE). &lt;STRONG&gt;A minimum of 691 confirmed primary outcome events are required&lt;/STRONG&gt; to provide 90% power with a one-sided α level of 0.025, assuming equal risk between the placebo and empagliflozin groups. With a minimum of 691 events, the trial will also have at least 80% power to detect a hazard ratio of 0.785 (corresponding to a 21.5% risk reduction in CV outcome events) for the primary outcome."&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;SPAN&gt;So actually how to get the number of 691 as stated in the article?&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;SPAN&gt;Thanks a lot for your kinda help.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN&gt;Trang&amp;nbsp;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;</description>
      <pubDate>Mon, 19 Jul 2021 09:15:59 GMT</pubDate>
      <guid>https://communities.sas.com/t5/Statistical-Procedures/Calculate-Sample-size-for-non-inferiority-clinical-trial-with/m-p/754938#M36752</guid>
      <dc:creator>Minhtrang</dc:creator>
      <dc:date>2021-07-19T09:15:59Z</dc:date>
    </item>
  </channel>
</rss>

